

**SUPPORTING INFORMATION FOR:**

## **Effective Capture of Circulating Tumor Cells from a Transgenic Mouse Lung Cancer Model using Dendrimer Surfaces Immobilized with anti-EGFR**

Ja Hye Myung<sup>1</sup>, Monic Roengvoraphoj<sup>2</sup>, Kevin A. Tam<sup>1</sup>, Tian Ma<sup>3</sup>, Vincent A. Memoli<sup>4</sup>, Ethan Dmitrovsky<sup>2,3,5</sup>, Sarah J. Freemantle<sup>3</sup>, and Seungpyo Hong<sup>1,6\*</sup>

<sup>1</sup>Department of Biopharmaceutical Sciences, College of Pharmacy, The University of Illinois, Chicago, IL 60612

<sup>2</sup>Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756

Departments of <sup>3</sup>Pharmacology & Toxicology, and <sup>4</sup>Pathology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03753

<sup>5</sup>Departments of Thoracic/Head and Neck Medical Oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

<sup>6</sup>Integrated Science and Engineering Division, Underwood International College, Yonsei University, Incheon, KOREA 406-840

\* Corresponding Author: Prof. Seungpyo Hong,

E-mail: sphong@uic.edu

Tel.: +1 312 413 8294 Fax: +1 312 996 0098

### **Table of contents**

**Table S1. Dissociation rate constants of PEGylated and dendrimer-coated surfaces functionalized with anti-EGFR, obtained by observing the surface detachment of the captured ED-1 and ED1-SC cells over static agitation.**

**Table S2. Histology results and the measured numbers of CTCs captured from blood samples of healthy controls and transgenic mice.**

**Figure S1. Representative fluorescence images of the captured CTCs from the blood samples of (a) healthy and (b) transgenic mice using an anti-EGFR-G7 dendrimer-immobilized surface.**

**Table S3. Histology results and the measured numbers of CTCs captured from blood samples of vehicle-treated transgenic mice, control locked nucleic acid-treated transgenic mice, and anti-miR-31 locked nucleic acid-treated transgenic mice.**

**Table S1. Dissociation rate constants of PEGylated and dendrimer-coated surfaces functionalized with anti-EGFR, obtained by observing the surface detachment of the captured ED-1 and ED1-SC cells over static agitation. The dissociation rate constants ( $k_d$ ) were calculated based on the number of the remaining cells on the surface upon agitation, relative to the initial number of bound cells before agitation, indicating relative binding strengths between the cells and the surfaces. Our data show that the binding between the cancer cells and the anti-EGFR-dendrimer-immobilized surface is substantially more stable than that on the anti-EGFR-PEG-coated surface.**

| Cell lines | $k_d$ [ $\text{min}^{-1}$ ] |      | Fold enhancement |
|------------|-----------------------------|------|------------------|
|            | PEG                         | G7   |                  |
| ED-1       | 2.81                        | 1.89 | 1.5              |
| ED1-SC     | 1.14                        | 0.89 | 1.4              |


**Table S2. Histology results and the measured numbers of CTCs captured from blood samples of healthy controls and transgenic mice.**

a) Healthy Controls

| Identification # | CTC# | Histology   | Age        |
|------------------|------|-------------|------------|
| C1               | 1.14 | Normal lung | ~ 3 months |
| C2               | 3.22 | Normal lung | ~ 3 months |
| C3               | 6.67 | Normal lung | ~ 6 months |
| C4               | 7.6  | Normal lung | ~ 6 months |
| C5               | 6.75 | Normal lung | ~ 6 months |
| C6               | 0.75 | Normal lung | ~ 6 months |

b) Transgenic Mice

| Identification # | CTC#   | Histology         | Age         | Gender |
|------------------|--------|-------------------|-------------|--------|
| 1                | 74     | Macroscopic tumor | ~ 28 months | Female |
| 2                | 29.67  | Macroscopic tumor | ~ 21 months | Male   |
| 3                | 142.75 | Macroscopic tumor | ~ 26 months | Male   |
| 4                | 50.22  | Macroscopic tumor | ~ 25 months | Female |
| 5                | 110.33 | Macroscopic tumor | ~ 28 months | Female |
| 6                | 45.57  | Macroscopic tumor | ~ 9 months  | Male   |
| 7                | 74.78  | Macroscopic tumor | ~ 9 months  | Male   |



**Figure S1. Representative fluorescence images of the captured CTCs from the blood samples of (a) healthy and (b) transgenic mice using an anti-EGFR-G7 dendrimer-immobilized surface.** CTCs are identified as cytokeratin-positive (red fluorescence), CD45-negative (green fluorescence), and DAPI (blue fluorescence)-positive cells, which are marked with white arrows on the images. Leukocytes are defined as cytokeratin-negative, CD45-positive, and DAPI-positive cells. The images show that significantly more CTCs are captured from the transgenic mouse blood, compared to the healthy control. Scale bar = 100  $\mu$ m

**Table S3. Histology results and the measured numbers of CTCs captured from blood samples of vehicle-treated transgenic mice, control locked nucleic acid-treated transgenic mice, and anti-miR-31 locked nucleic acid-treated transgenic mice.**

a) Vehicle-treated transgenic mice (Control)

| Identification # | CTC#  | Histology                                     |
|------------------|-------|---|
| 1                | 6     | Focal dysplasia, mild lymphocytic pneumonitis |
| 2                | 3.11  | Normal lung                                   |
| 3                | 55.11 | Papillary adenocarcinoma, grade 2             |
| 4                | 23.67 | Normal lung                                   |
| 5                | 2.67  | Normal lung                                   |

b) Control locked nucleic acid (C-LNA)

| Identification # | CTC#  | Histology                         |
|------------------|-------|-----------------------------------|
| 1                | 86.57 | Normal lung                       |
| 2                | 48.33 | Papillary adenocarcinoma, grade 2 |
| 3                | 60.44 | Papillary adenocarcinoma, grade 2 |
| 4                | 19.56 | Normal lung                       |
| 5                | 16.33 | Normal lung                       |

c) Anti-miR-31 locked nucleic acid (a31-LNA)

| Identification # | CTC#  | Histology                              |
|------------------|-------|--|
| 1                | 7.5   | Mild lymphocytic pneumontis            |
| 2                | 2.67  | Normal lung                            |
| 3                | 3.56  | Carcinoid vs adenocarcinomama, grade 1 |
| 4                | 7.13  | Normal lung                            |
| 5                | 11.11 | Normal lung                            |
| 6                | 19.67 | Normal lung                            |